The European Commission has requested EFSA to assess animal diseases according to the criteria as laid down in Articles 5, 7, 8 and Annex IV for the purpose of categorisation of diseases in accordance with Article 9 of the Regulation (EU) No 2016/429 (Animal Health Law). This scientific opinion addresses the ad hoc method developed for assessing any animal disease for the listing and categorisation of diseases within the Animal Health Law (AHL) framework. The assessment of individual diseases is addressed in distinct scientific opinions that are published separately. The assessment of Articles 5, 8 and 9 criteria is performed on the basis of the information collected according to Article 7 criteria. For that purpose, Article 7 criteria were structured into parameters and the information was collected at parameter level. The resulting fact sheets on the profile and impact of each disease were compiled by disease scientists. A mapping was developed to identify which parameters from Article 7 were needed to inform each Article 5, 8 and 9 criterion. Specifically, for Articles 5 and 9 criteria, a categorical assessment was performed, by applying an expert judgement procedure, based on the mapped information. The judgement was performed by EFSA Panel experts on Animal Health and Welfare in two rounds, individual and collective judgement. The output of the expert judgement on the criteria of Articles 5 and 9 for each disease is composed by the categorical answer, and for the questions where no consensus was reached, the different supporting views are reported.
, hereinafter referred as AHL, provides the list of animal diseases to which the rules set out in the AHL apply. These rules include the categorisation of those diseases into different groups depending on the appropriate measures, as provided for in Article 9 of that Regulation.
In addition to the list of five significant diseases laid down in Article 5 (1) of the AHL, there is a list of other diseases in Annex II that is amendable by the Commission by means of a delegated act.
Furthermore, there are transmissible animal diseases for which certain control or trade measures apply today but are not included in the mentioned Annex II and diseases that might be relevant for forthcoming Union intervention.
Criteria for listing of animal diseases are laid down in Article 5(3), for the assessment in Article 7 and for the categorisation of animal diseases in Annex IV of the AHL.
Those criteria constitute the benchmarks for the exercises of listing and categorisation and for determining the disease prevention and control rules to be applied to the different categories of listed diseases.
Furthermore, Article 8 of the AHL envisages that disease specific rules for listed diseases apply to listed animal species. Those species, or groups of animal species, are those that are either susceptible species or they have the capability to carry specific diseases.
Specific criteria for listing of species are provided for in Article 8(3) of the AHL. The Commission needs a scientific advice to enable the assessment of the following diseases within the framework of the listing and categorisation according to the AHL, although the same methodology could be applied in the future for further request: The criteria, provided in the Appendix A of this opinion, shall be used as a basis for the analytical assessment. The risk manager needs an updated scientific advice in order to:
• assess if the above mentioned animal diseases are diseases for which control measures at the European Union (EU) level are justified;
• proceed profiling each disease with a view to its categorisation;
• assign listed species to the diseases identified as relevant for the EU intervention.
In view of the above, and in accordance with Article 29 of Regulation (EC) No 178/2002, the Commission asks EFSA for a scientific opinion: 1) ToR 1: for each of the diseases an assessment, following the criteria laid down in Article 7 of the AHL, on its eligibility to be listed for Union intervention as laid down in Article 5(3) of the AHL. 2) ToR 2: for each of those diseases which was found eligible to be listed for Union intervention: a) an assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of categorisation of diseases in accordance with Article 9 of the AHL; b) a list of animal species that should be considered candidates for listing in accordance with Article 8 of the AHL.
Interpretation of the Terms of Reference (ToR)
An assessment of the animal diseases listed in Section 1.1 according to the criteria of Articles 5, Annex IV for the purpose of categorisation of diseases in accordance with Article 9 2 and 8 of the AHL is requested by the European Commission in five similar mandates, to be done on the basis of the information available according to the assessment criteria of Article 7 (profile and impact). The criteria of Articles 5, 7, 8 and 9 , are provided in the Appendix A of the present opinion.
The first ToR requires an assessment of each disease against the eligibility criteria as listed in Article 5. The Article 5 of the Regulation (EU) No 429/2016 provides the list of animal diseases to which the rules set out in the AHL apply. A disease is eligible to be listed if it has been assessed according to the criteria listed in Article 7 and if it meets the criteria of Article 5 of the AHL. The criteria of Article 7 concern the disease profile, impact of the disease, potential to generate a crisis situation and its potential for use in bioterrorism, the feasibility, availability, effectiveness and the impact of disease prevention and control measures.
The second ToR requires an assessment of each disease against the criteria as in Annex IV of the AHL for the purpose of categorisation of diseases in accordance with Article 9. These criteria provide the rules for the categorisation of the diseases into different groups depending on the appropriate measures (eradication, control, etc.) , as provided for in Article 9 of the AHL. There are five categories in Article 9 of the AHL, each with a defined purpose as follows:
• category A: listed diseases that do not normally occur in the Union and for which immediate eradication measures must be taken as soon as they are detected.
• category B: listed diseases which must be controlled in all Member States with the goal of eradicating them throughout the Union.
• category C: listed diseases which are of relevance to some Member States and for which measures are needed to prevent them from spreading to parts of the Union that are officially disease-free or that have eradication programmes for the listed disease concerned.
• category D: listed diseases for which measures are needed to prevent them from spreading on account of their entry into the Union or movements between Member States.
• category E: listed diseases for which there is a need for surveillance within the Union.
Each category foresees the application of certain disease prevention and control rules to the respective listed diseases when the disease in question fulfils the criteria laid down in the relevant Section of Annex IV of AHL (Sections 1-5 which correspond to categories A-E, respectively).
The same ToR requires the provision of the list of animal species that should be considered candidates for listing in accordance with Article 8(3). This Article envisages that specific rules for listed diseases apply to listed animal species. Those species, or groups of animal species, are those that are either susceptible species or those that have the capability to carry specific pathogenic agents.
For the first ToR, the disease and impact profile following Article 7 criteria requires compilation for each disease. This represents the baseline information for the assessment as requested by ToR 1 and ToR 2, i.e. to enable determination of the eligibility for listing the disease in the AHL, the category into which each of the diseases fits according to Article 9 of AHL, and the animal species that should be considered as relevant for that disease.
The use and the purpose of the assessment for the European Commission should be to provide clear and robust information to qualify the importance of each disease in the Union, and if justified, which measures should be taken in the EU.
The answer to the mandates will be structured in one document providing the description of the methodology for the assessment of diseases and an individual document providing the information and assessment for each disease.
Data and methodologies
In order to address the ToRs as provided by the Commission, an ad hoc method of assessment has been developed and used for each disease for collecting information on the profile and impacts of the targeted diseases and conducting the assessment of the disease within the framework of AHL.
The framework used to elaborate the method for information collection and assessment of diseases are the criteria laid down in Articles 5, 7, 8(3) and 9 of the AHL as provided to EFSA and as reported in the Appendix A of the present opinion.
The AHL foresees that the assessment of each disease, based on the criteria listed in Articles 5 (eligibility for listing), 9 (categorisation into control classes) and 8 (listing species) should be performed on the basis of the information collected according to Article 7 (disease profile and impacts). Accordingly, the proposed and developed method consists of three main steps as summarised in the following Table 1: These steps are described in detail in the following sections. 
Data collection for disease profile and impacts based on Article 7 criteria
In order to compile the information on (a) the diseases profile, (b, c) the impact of the diseases, (d) the availability, feasibility and effectiveness of control measures, and (e) the impact of disease prevention and control measures according to Article 7 of AHL,
• the Article 7 criteria (in Appendix A) are broken down and structured into parameters;
• data/information is collected at parameter level by selected disease scientists and drafted in a fact sheet format.
Restructuring of Article 7 criteria into parameters
For each criterion in Article 7 of the AHL, subcriteria are identified on which information is needed to fully characterise the disease. For each subcriterion, a list of parameters characterising the subcriterion and related parameters are defined by the working group (WG) experts. Existing frameworks on disease and impact assessment using a multi criteria approach are consulted in order to support the definition and identification of appropriate parameters to assess diseases according to Article 7 criteria of the AHL (DEFRA, 2006; RIVM, 2006; WHO, 2006; European Commission, 2007; ETPGAH, 2007 ; Council of the European Union, 2008; Krause et al., 2008; Cardoen et al., 2009; Havelaar et al., 2010; OIE, 2010; Del Rio Vilas et al., 2011; ECDC, 2011; DISCONTOOLS, 2012; EFSA BIOHAZ Panel (2012) ; FAO, 2012; Humblet et al., 2012; Ng and Sargeant, 2012; Cox et al., 2013; Del Rio Vilas et al., 2013; Ng and Sargeant, 2013; ECDC, 2015; Gao et al., 2015; McFadden et al., 2016; Ng and Sargeant, 2016) . The result of the restructuring of Article 7 is shown in Table 2 .
Concerning the criteria e(i) and e(ii), i.e. the impact of disease prevention and control measures as regards the costs for affected sectors and the economy as a whole, and the societal acceptance, respectively, an assessment of all direct and indirect costs cannot be provided in this opinion in a general framework, since the analysis of costs of control measures and of their societal acceptance is not science-driven but it is linked to the different socioeconomical contexts and to the different management decisions to be applied. In order to assess this criterion, a description is provided about the elements characterising the costs for the affected sectors and the types of prevention and control measures that may entail issues about societal acceptance, by bringing some cases studies, where available.
Regarding the criterion about impact of disease prevention and control measures as regards environment and biodiversity, the outcomes of interest concern the use and potential residues of biocides and medical treatments and reference to already available environmental risk assessment is provided where available.
The evidence collected on the different criteria is summarised in narrative and in summary tables.
Disease fact sheet compilation
Disease fact sheet A disease fact sheet is defined as a document containing all relevant information on a specific disease following the structure of the Article 7 criteria of the AHL. The aim is to draft a comprehensive, succinct and up to date fact sheet on the profile, impact, and control options of each disease requested by the mandate. The fact sheet covers all criteria of Article 7 of the AHL according to the parameters as mentioned above.
The fact sheet is used as scientific basis to allow the EFSA panel of experts on animal health and welfare to assess the criteria for listing and categorisation of a certain disease in the framework of AHL (Articles 5 and 9 of AHL), and for the identification of the animal species concerned (Article 8 of the AHL).
Disease Scientist
The disease fact sheet compilation has been outsourced to disease scientists (DSs). A DS is a scientist who has the expertise to retrieve, extract, collate and interpret relevant scientific information related to a specific disease, covering all AHL (Article 7) criteria and related parameters.
The required expertise of the DS should cover the criteria on the disease profile as laid down in Article 7 of the AHL, which are listed below:
• Epidemiology • Economics of animal health and production • Ecology/ecosystems/dependencies/impact on The above listed fields of expertise, deemed to be necessary, implies also certain knowledge on the following domains:
The expertise of a candidate DS is expected to cover most of the required fields for at least one of the diseases that EFSA is requested to assess.
DSs with the required scientific profile have been identified and selected by a search in databases of scientific literature, by giving priority to authors of the most recent publications and reviews and by considering scientists working in the OIE, EU or national reference laboratories.
In this specific case of the AHL disease profiling, the search string for retrieving the relevant literature had to be general enough to cover all aspects of each disease. The search string used is the following:
[ Once the list of authors is returned by the search, the selection of the DS among the potential candidates, as described above, is based on number of publications, date of publication, affiliation and availability.
Fact sheet compilation

Sources of information:
The DS could use scientific literature as sources of information, giving priority to peer-reviewed literature and based on the evidence pyramid, where most reliance can be given to systematic reviews and meta-analyses, followed by critically-appraised topics with syntheses, critically-appraised articles (synopses), randomised controlled trials, cohort studies, case-control studies, case-series and reports, and expert opinions. Least reliance can be given to the latter. Furthermore, the following sources of information could be used:
• EFSA databases (Data Collection Framework and/or ad hoc databases)
• EFSA scientific outputs published on the same topic (Scientific Opinions, Scientific Reports, Technical Reports, other outputs)
• EMA outputs relevant for treatments and vaccination • ECDC outputs relevant for the zoonotic aspects • EUROSTAT for information related to trade • Information by MSs • OIE manuals and any other output relevant for the diagnostic tests and the vaccines The DS should also identify for which Article 7 criteria and related parameters the data and the information available, at the time of the fact sheet compilation, are lacking or not up to date. The data and the information should be combined and narratively described, interpreted and commented, following the structure of the fact sheet. The DS should complete and update each of them by reporting in detail the sources of information used.
Completed fact sheets are then reviewed by two independent experts selected from the EFSA Panel on Animal Health and Welfare (AHAW) experts or from the EFSA ad hoc WG, whose role is to assess the integrity of the documents. The reviewers assess that the content of the fact sheets sufficiently covers what is requested by the parameters of Article 7, and highlighted any knowledge gap, any missing or wrong information, any missing critical or relevant references and possible expert bias introduced by the DS. The comments provided by reviewers are addressed and endorsed by DSs.
2.2.
Use of Article 7 criteria and parameters to inform Articles 5, 8 and 9 criteria: mapping As mentioned, the assessment of each disease, based on the criteria listed in Article 5 (eligibility for listing), should be performed on the basis of the information collected according to Article 7. For this purpose, a mapping is developed to identify which elements from Article 7 are needed to inform each Article 5 criterion. The table based on Article 7 criteria at parameter level (disease fact sheet) is used to build a matrix linking sets of relevant Article 7 parameters to each relevant criterion of Article 5.
Likewise, the assessment of the diseases in view of their categorisation based on Article 9, and of animal species that should be considered candidates for listing in accordance with Article 8 of the AHL are performed on the basis of the information collected under Article 7. In the same way, a similar mapping is developed to build a matrix linking sets of relevant Article 7 parameters to each relevant criterion of Article 9 and Article 8. For Article 8, the mapped Article 7 information constitutes directly the outcome of the assessment.
2.3.
Disease assessment according to Article 5 and Article 9
The assessment of each disease according to Articles 5 and 9 criteria is carried out using the procedure of expert judgement that involves expert selection and judgement as described below.
Expert selection
The AHAW Panel is composed of 21 members who have been selected according to their expertise on animal health and welfare, and their absence of conflict of interest has been screened according to the EFSA rules on declarations of interest for the experts. 
Assessment method
Expert judgement is performed using the Individual and Collective Behavioural Aggregation (ICBA) approach described below. Experts are individually provided with the disease fact sheet prior to the judgement together with interpretations and definitions of some wording used in Articles 5 and 9.
The criteria of Articles 5 and 9 are phrased in a way that they could be translated into questions to which Yes/No answers could be given (fulfilment check). In order to facilitate the risk managers' decision for listing and categorisation, a Yes/No/na (na: 'not available', meaning insufficient evidence or irrelevant to judge) assessment for the criteria of Articles 5 and 9 was developed. Accordingly, an assessment table is constructed, where a mapping of Article 5 and 9 in relation to Article 7, with the possible Yes/No/na outcomes, is displayed.
Using that assessment table, the experts indicate their Y/N or 'na' judgement on each criterion of Articles 5 and 9, and they may provide the different reasoning arguments supporting their judgement.
The ICBA method to perform the expert judgement for each disease is implemented in two rounds:
Round 1: Individual judgement Each expert performs his/her individual judgement. On the basis of the evidence collected from Article 7 criteria/parameters and mapped into Article 5 and Article 9 criteria, the experts are asked individually to provide categorical answers (Y/N/na) (using Table 2 and Appendix B). For questions where no consensus is reached at the individual level, the experts are requested to provide the view/ reasoning leading them to the final Y/N/na answer. Round 2: Collective judgement
The collective judgement consists of a behavioural aggregation where the individual judgements produced in Round 1 are discussed in a physical meeting, where additional material/information may be supplied by the experts present, in order to seek for consensus. Following the discussion, for each Article 5 and 9 criterion, the final answer is provided (consensus for Yes, No or 'na' or no consensus) together with the supporting views where the consensus is not reached. The following are taken into account:
• only the responses from experts having taken part in both individual and collective judgement are counted per question in the final output;
• the questions where full consensus is reached during the individual judgement are not further discussed in the physical meeting.
The overall output of the judgement achieved for each Article 5 and 9 criterion for each disease is composed by a categorical answer (Y/N/na), and for the no consensus questions, the outcome includes all the supporting views and the %Y, %N and %na.
Fact sheet amendment: following the individual judgment, and during the collective judgment until the final adoption, additional information or clarification of certain points can be added into the fact sheet for consideration. The fact sheet can also be revised when necessary.
Reassessment: In the case of substantial changes in the fact sheet that can impact the outcome of the assessment already done, the target question has to be reassessed under collective judgment (not necessarily involving the same judges).
Results
The main objective of this work is to develop an ad hoc methodological approach fit for the purpose of assessing each disease under rules prescribed in the AHL. As a result, the method that has been developed consists in three chronological main steps as summarised in Figure 1 and described below.
The three processes in Figure 1 are described in detail in the following Sections 3.1, 3.2 and 3.3. 
Collection of information
At the commencement of the assessment of any disease, a disease scientist (DS) is selected as described in Section 2. The DS is provided with a template of a fact sheet to be completed following the framework determined from the structured Article 7 (input) (see Table 2 ). The result of breaking down the Article 7 criteria of the AHL into sub-criteria and parameters is given below in Table 2 .
The DS collects information and drafts the disease fact sheet according to the criteria they have been provided (structured Article 7 criteria of the AHL).
The disease fact sheet is then reviewed by two independent reviewers (AHAW Panel experts or WG experts) and DS endorses the comments provided.
Input: Structured Article 7 (Table 2) . Output: Disease profile and impacts in a fact sheet format (Result for ToR 1). Mapping of Article 7 criteria in relation to Article 5, Article 9 and Article 8 criteria
The disease fact sheet as in step 1 (structured table of Article 7 criteria) is reorganised using mapping matrices that allow assigning each set of information related to each Article 7 criteria (and related parameters) to the relevant Articles 5, 9 and 8 criteria. The mapping matrices providing each criterion of Articles 5, 9 and 8 as a function of Article 7 criteria (and related parameters) are given below in Tables 3, 4 and 5, respectively.
As a result, the disease fact sheet is reshaped into disease assessment table, an example is shown in Table 6 where the first question of Article 5 is reported, while, in Appendix B, the tables for all other questions are reported.
Output: Mapping matrices (Tables 3, 4 and 5) and a disease assessment table (Table 6 ). For Article 8, mapping of the disease fact sheet into Table 5 provides directly the outcome of the assessment. 'case-fatality rate' is considered.
Assessment of animal diseases based on AHL criteria
www.efsa.europa.eu/efsajournal In terrestrial animals: it does not result in high morbidity and negligible or no mortality, often the most observed effect is production loss;
In aquatic animals: it has high morbidity and usually low mortality, often the most observed effect is production The disease in question has a significant impact on the economy of the Union, causing substantial costs, mainly related to its direct impact on the health and productivity of animals
The disease in question has a significant impact on the economy of the Union, mainly related to its direct impact on the health and productivity of animals 
www.efsa.europa.eu/efsajournal
In Appendix B, the instructions for the judgement including definitions and interpretations of terms and questions are provided.
Disease assessment
The disease assessment is performed using the ICBA approach as described in Section 2 on methodology. In the first round of judgement, the disease assessment table (Table 6 ) in step 2 is provided to experts (AHAW panel experts) for individual assessment of the disease. In the second round of judgement, the results of the expert judgement obtained in first round are used for the collective behavioural aggregation.
The final result of the expert judgement on each criterion of article 5 and article 9 is the output of the collective judgement, which combines the outcome of the individual judgements, their discussion and any additional relevant material known to the experts participating in the judgement. The final outcome can be revised by the AHAW Panel on the basis of any new available evidence before the adoption of the scientific opinion, and the judgment can be amended accordingly. The result of assessment is reported in Tables 7 and 8. As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article 5 if it fulfils all criteria indicated in point A and at least one criterion as in point B of Article 5(3) (see Appendix A.2). Likewise, a disease is considered to belong or classified in a category according to Article 9 if it fulfils all criteria indicated at points a and b and at least one of the criteria indicated at <Information from the fact sheet> Table 7 : Final result of the expert judgement on each criterion of Article 5 or Article 9. points c, d, e as in Annex IV (see Appendix A.3). According to the assessment methodology, a criterion is considered fulfilled when the outcome is 'Yes'. For each outcome without consensus, an additional table (Table 8) is provided followed by the detailed list of different supporting views.
For each disease, the final results of the assessment according to the assessment steps as shown in Figure 1 are the following:
• Disease fact sheet: provides information on the disease profile and impacts. The format is shown in Table 2 .
• Disease assessment according to Article 5: it provides information on the eligibility of the disease to be listed. The format is shown in Tables 6 and 7.
• Disease assessment according to Article 9: it provides information on the compliance of the disease with each of the criteria in Annex IV to the AHL for the purpose of categorisation in accordance with Article 9. The format is shown in Tables 6 and 7.
• Disease assessment according to article 8: a list of animal species that should be considered candidates for listing in accordance with Article 8 of the AHL, based on the criteria as displayed in Table 5 of the present document.
The assessment results are drafted in a separated opinion, one for each disease.
Conclusions
• An ad hoc method for disease listing and categorisation according to the framework of Articles 7, 5 and Annex IV in accordance with Articles 9 and 8 of the AHL has been developed in order to allow the AHAW Panel to perform the requested assessment on each disease.
• The assessment methodology includes: (i) the procedure for collecting the data and compiling the information in a disease fact sheet, (ii) the mapping matrices of Articles 5, 9 and 8 based on Article 7 providing the directions for use of the relevant information from the disease fact sheets, and (iii) the expert judgement for the disease assessment for listing and categorisation.
• This methodology is used for the following assessment steps: the assessment according to the Article 7 criteria (disease fact sheet); the expert judgement according to Articles 5 and 9 criteria; and the assessment according to Article 8 criteria on the species concerned by the disease, which is derived from the related criteria of the fact sheet.
• The expert judgement approach that was followed during the disease assessment combines the individual and collective knowledge and opinion of experts and seeks consensus, when possible.
• This method has been developed and adapted to a set of predefined and prestructured criteria from the legislative text of the AHL. Therefore, the structure of the method follows the legislative texts of the AHL. Initially, data are collected on the disease profile and impacts according to Article 7, next, the eligibility of the disease for listing is assessed and categorised according to Articles 5 and 9, respectively, and finally the animal species candidates for listing are assessed according to Article 8.
• Finally, the assessment framework as proposed above (see Figure 1) does not target nor exclude a formal and automated procedure. i) foot and mouth disease; ii) classical swine fever; iii) African swine fever; iv) highly pathogenic avian influenza; v) African horse sickness; and b) the listed diseases set out in the list in Annex II.
2. The Commission shall adopt delegated acts in accordance with Article 264 concerning amendments to the list referred to in point (b) of paragraph 1 of this Article.
3. A disease shall be included on the list referred to in point (b) of paragraph 1 of this Article if it has been assessed in accordance with Article 7 and it meets: a) all of the following criteria: i) scientific evidence indicates that the disease is transmissible; ii) animal species are either susceptible to the disease or vectors and reservoirs thereof exist in the Union; iii) the disease causes negative effects on animal health or poses a risk to public health due to its zoonotic character; iv) diagnostic tools are available for the disease; and v) risk-mitigating measures and, where relevant, surveillance of the disease are effective and proportionate to the risks posed by the disease in the Union; and b) at least one of the following criteria:
i) the disease causes or could cause significant negative effects in the Union on animal health, or poses or could pose a significant risk to public health due to its zoonotic character; ii) the disease agent has developed resistance to treatments which poses a significant danger to public and/or animal health in the Union; iii) the disease causes or could cause a significant negative economic impact affecting agriculture or aquaculture production in the Union; iv) the disease has the potential to generate a crisis or the disease agent could be used for the purpose of bioterrorism; or v) the disease has or could have a significant negative impact on the environment, including biodiversity, of the Union.
4. The Commission shall adopt delegated acts in accordance with Article 264 concerning the removal of a disease from the list referred to in point (b) of paragraph 1 of this Article when that disease no longer fulfils the criteria provided for in paragraph 3 of this Article.
5. The Commission shall review the listing of each disease in the light of newly available significant scientific data.
A.3.
Annex IV -Criteria for the application of the disease prevention and control rules referred to in Article 9(1) to diseases listed in accordance with Article 5
The scope of this Annex is to detail the criteria to be considered by the Commission when determining the disease prevention and control rules to be applied to the different categories of diseases listed in accordance with Article 5.
The process of categorisation shall take into account the profile of the disease in question, the level of the impact of that disease on animal and public health, animal welfare and the economy, and the availability, feasibility and effectiveness of the diagnostic tools and different sets of disease prevention and control measures provided for in this Regulation with respect to the disease.
A.3.1.
Section 1 Criteria for the application of the disease prevention and control rules referred to in point (a) of Article 9(1)
The diseases for which the disease prevention and control rules referred to in point (a) of Article 9 (1) apply shall be considered to have the most severe animal health, public health, economic, social or environmental impacts on the Union. Those diseases need to fulfil the following criteria: a) the disease in question is: and i) not present in the territory of the Union; ii) present only in exceptional cases (irregular introductions); or iii) present in only in a very limited part of the territory of the Union; b) the disease in question is highly transmissible; in addition to direct and indirect transmission, there may also be possibilities of airborne, waterborne or vector-borne spread. The disease may affect multiple species of kept and wild animals, or a single species of kept animals of economic importance, and may result in high morbidity and significant mortality rates.
In addition to the criteria set out in points (a) and (b), those diseases need to fulfil one or more of the following criteria: c) the disease in question has a zoonotic potential with significant consequences for public health, including epidemic or pandemic potential or possible significant threats to food safety; d) the disease in question has a significant impact on the economy of the Union, causing substantial costs, mainly related to its direct impact on the health and productivity of animals; e) the disease in question has a significant impact on one or more of the following: i) society, with in particular an impact on labour markets; ii) animal welfare, by causing suffering to large numbers of animals; iii) the environment, due to the direct impact of the disease or due to the measures taken to control it; iv) in the long term, biodiversity or the protection of endangered species or breeds, including the possible disappearance of, or long-term damage to, those species or breeds.
A.3.2. Section 2 Criteria for the application of the disease prevention and control rules referred to in point (b) of Article 9(1)
The diseases for which the disease prevention and control rules referred to in point (b) of Article 9 (1) apply shall be controlled in all Member States with the goal of eradicating them throughout the Union.
Those diseases need to fulfil the following criteria: a) the disease in question is endemic in nature and is present in the whole or part of the Union territory. However, several Member States or zones of the Union are free of the disease; and b) the disease is moderately to highly transmissible; in addition to direct and indirect transmission, there may also be possibilities of airborne, waterborne or vector-borne spread. It may affect single or multiple animal species and may result in high morbidity, with in general low mortality.
In addition to the criteria set out in points (a) and (b), those diseases need to fulfil one or more of the following criteria: c) the disease in question has a zoonotic potential with significant consequences for public health, including epidemic potential or possible significant threats to food safety; d) the disease in question has a significant impact on the economy of the Union causing substantial costs, mainly related to its direct impact on the health and productivity of animals; e) the disease has a significant impact on one or more of the following: i) society, with in particular an impact on labour markets; ii) animal welfare, by causing suffering to large numbers of animals; iii) the environment, due to the direct impact of the disease or due to the measures taken to control it; iv) in the long term, biodiversity or the protection of endangered species or breeds, including the possible disappearance of, or long-term damage to, those species or breeds.
A disease to which the measures referred to in point (a) of Article 9(1) apply, which has not been successfully and promptly eradicated in a part of the Union, and has, in that part of the Union, obtained an endemic character, may be subject to disease prevention and control measures under point (b) of Article 9(1), in that part of the Union.
A.3.3.
Section 3 Criteria for the application of the disease prevention and control rules referred to in point (c) of Article 9(1)
The diseases for which the disease prevention and control rules referred to in point (c) of Article 9 (1) apply are of relevance to some Member States and measures are needed to prevent them from spreading to parts of the Union that are officially disease-free or that have eradication programmes for the listed disease in question.
Those diseases need to fulfil the following criteria: a) in terrestrial animals, the disease in question is endemic in nature and is present in the whole or part of the Union territory; or in aquatic animals, several Member States or zones of the Union are free of the disease; and b) i) in terrestrial animals, the disease in question is moderately to highly transmissible, mainly through direct and indirect transmission. The disease mainly affects multiple or single animal species, usually does not result in high morbidity, and has a negligible or no mortality rate. Often the most observed effect is production loss; ii) in aquatic animals, the disease is moderately to highly transmissible, mainly through direct and indirect transmission. The disease affects multiple or single animal species and may result in high morbidity and usually low mortality. Often the most observed effect is production loss.
In addition to the criteria set out in points (a) and (b), those diseases need to fulfil one or more of the following criteria: c) the disease in question has a zoonotic potential with significant consequences for public health, or possible threats to food safety; d) the disease in question has a significant impact on the economy of parts of the Union, mainly related to its direct impact on certain types of animal production systems. e) the disease in question has a significant impact on one or more of the following: i) society, with, in particular, an impact on labour markets; ii) animal welfare, by causing suffering to large numbers of animals; iii) the environment, due to the direct impact of the disease or of the measures taken to control it; iv) in the long term, biodiversity or the protection of endangered species or breeds, including the possible disappearance of, or long-term damage to, those species or breeds.
A.3.4. Section 4 Criteria for the application of the disease prevention and control rules referred to in point (d) of Article 9(1)
The disease prevention and control rules referred to in point (d) of Article 9(1) shall apply to diseases that fulfil the criteria set out in Sections 1, 2 or 3 and to other diseases fulfilling the criteria set out in Section 5 where the risk posed by the disease in question can be effectively and proportionately mitigated by measures concerning movements of animals and products in order to prevent or limit its occurrence and spread.
A.3.5.
Section 5 Criteria for the application of the disease prevention and control rules referred to in point (e) of Article 9(1)
The disease prevention and control rules referred to in point (e) of Article 9(1) shall apply to diseases that fulfil the criteria set out in Sections 1, 2 or 3 and to other diseases where surveillance of the disease is necessary for reasons relating to animal health, animal welfare, human health, the economy, society or the environment.
A.4. Article 8 -Listed species
Animal species or groups of animal species shall be added to the list if they are affected or if they pose a risk for the spread of a specific listed disease because: a) they are susceptible to a specific listed disease or scientific evidence indicates that such susceptibility is likely; or b) they are vector species or reservoirs for that disease, or scientific evidence indicates that such role is likely.
For the disease related to case 2 the different type of impact (current and potential, as explained above), is assessed separately in the table collecting the answers of the judges or explained in the reasoning points.
Interpretation of question D in Article 9 'the risk posed by the disease in question can be effectively and proportionately mitigated by measures concerning movements of animals and products in order to prevent or limit its occurrence and spread': for exotic diseases, the assessment of the effectiveness of movement of animals and products to mitigate the risk should take into account also the control of movements into the EU (import checks).
B.3.2. Article 9 Question 1
The answer to the question 1CAq can be Y only for diseases affecting aquatic animal species, therefore do not assess this question for diseases affecting terrestrial animal species The answer to the question 2.4CAq can be Y only for diseases affecting aquatic animal species, therefore do not assess this question for diseases affecting terrestrial animal species Questions 3 Question 2.4A the disease may results in high morbidity and significant mortality rates Answer Y ☐ N ☐ na ☐ Question 2.4B the disease may result in high morbidity and in general low mortality Answer Y ☐ N ☐ na ☐ Question 2.4C the disease usually does not result in high morbidity and has negligible or no mortality AND often the most observed effect of the disease is production loss Answer Y ☐ N ☐ na ☐ Question 2.4CAq the disease may result in high morbidity and usually low mortality AND often the most observed effect of the disease is production loss 
